Skip to main content
. 2021 Aug 23;12:692831. doi: 10.3389/fmicb.2021.692831

TABLE 1.

Sensitivity of SP-NLISA and control assays for testing of NP antigens in serums from COVID-19 patients.

Clinical typing Sample (Nb) SP-NLISA (Nb/%) Pt@AuNP ELISA (Nb/%) HRP-ELISA (Nb/%) Biodragon ELISA (Nb/%)
Severe 14 13 (92.8%) 10 (71.4%) 5 (35.7%) 5 (35.7%)
Mild 23 15 (65.2%) 11 (47.8%) 2 (8.7%) 2 (8.7%)
Overall 37 28 (75.7%) 21 (56.7%) 7 (18.9%) 7 (18.9%)